Vanguard vs. Fidelity: Is VIG or FDVV the Better Dividend ETF to Buy?

Fidelity High Dividend ETF (FDVV) and Vanguard Dividend Appreciation ETF (VIG) differ mainly on yield, cost, concentration and scale: FDVV yields 3.02% (expense ratio 0.15%), has $7.7B AUM, 119 holdings and a 1-year total return of 17.7%, while VIG yields 1.59% (expense ratio 0.05%), has $120.4B AUM, 338 holdings and a 1-year return of 15.1%. Both tilt heavily to technology and financials (tech ~26–30%, financials ~19–21%), but FDVV has a larger consumer-defensive exposure and greater performance skew from a large Nvidia position (6.2% of FDVV) that has materially boosted recent returns. The tradeoff is higher income and recent outperformance (FDVV) versus lower fees, broader diversification and steadier dividend-growth pedigree (VIG); choice depends on investors’ preference for yield/growth exposure versus fee-efficient dividend-growth diversification.

Analysis

Market structure: FDVV benefits active income-seeking flows and short-term growth chasing because it yields 3.02% and is concentrated (NVDA = 6.2%); VIG benefits buy-and-hold dividend-growth investors due to 0.05% fees and $120B AUM. FDVV’s smaller AUM ($7.7B) means inflows/outflows will move underlying large-cap tech names (NVDA, MSFT, AAPL) more, amplifying idiosyncratic moves and option implied volatility; dealers will widen spreads on FDVV quicker than on VIG.

Risk assessment: Tail risks include a 30–50% NVDA drawdown (AI shock/regulatory action) that would materially dent FDVV total return despite negligible dividend cash impact, and a faster-than-expected Fed tightening that compresses dividend-growth multiples. Near-term (days-weeks) risks cluster around NVDA earnings and Fed statements; medium-term (3–9 months) risks are ETF flows and rebalances; long-term (12+ months) risk is persistent rate regime that favors high-yield consumer defensive names over low-yield growth.

Trade implications: The clean relative-value is a market-neutral pair: short FDVV / long VIG to capture NVDA-concentration premium if NVDA mean-reverts; expect capture of 100–300 bps if NVDA falls 20–30% within 3–6 months. For income sleeves, a capped 2–4% allocation to FDVV is reasonable but hedge with 3-month put protection if NVDA weight >7% or FDVV outperforms VIG by >250 bps in 30 days.

Contrarian angle: Consensus treats FDVV as a “high-dividend” alternative; that is mis-specified — FDVV’s outperformance is growth/tech-driven, not dividend yield. If NVDA/AVGO rally pauses, FDVV could underperform materially; historical parallels: ETF concentration-led reversals in 2018–2020. Monitor NVDA weight, FDVV/VIG spread, and 1-month NVDA implied vol as early warning signals.

Key Decisions for Investors

• Establish a market-neutral pair trade: short 1–2% notional FDVV and long 1–2% VIG for a 3–6 month horizon to capture potential mean reversion in NVDA-driven outperformance; tighten if FDVV outperforms VIG by >300 bps in 30 days; target profit 100–300 bps, stop-loss at 400 bps adverse spread move.
• For income sleeve allocations, initiate a 3% position in FDVV (ticker FDVV) for yield (3.02%) but cap exposure and buy a 3-month 5% out-of-the-money put (or put spread) to limit drawdown to ~15% if NVDA weight rises above 7.5% or FDVV NAV drops >12% in 30 days.
• If constructive on dividend-growth cost-efficiency, rotate 2–4% from single-name NVDA exposure into VIG (ticker VIG) to lower fee drag (0.05% vs 0.15%) and reduce concentration; target rebalancing every quarter or if VIG five-day inflows exceed 0.5% of AUM.
• Use options to express short-vol / directional view: buy a 3–6 month FDVV put spread (sell farther OTM put to fund) sized to limit max loss to ~1% portfolio risk if expecting a tech drawdown tied to NVDA earnings or Fed hikes; unwind if NVDA implied vol compresses >30% from entry.